Get a free sample of Human Immunodeficiency Virus (HIV) Therapeutics Market
Thank you!
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Human Immunodeficiency Virus (HIV) Therapeutics Market
Thank you!
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Human Immunodeficiency Virus Therapeutics Market Size
The global human immunodeficiency virus therapeutics market size valued at USD 39 billion in 2024 and is projected to exhibit 3.5% CAGR from 2025 to 2034. High incidence of HIV infections, advances in therapeutic treatment options, growing support through government initiatives and health programs, and favorable regulatory approvals are driving the revenue growth in the market.
Regulatory bodies, such as the U.S. FDA, are approving innovative HIV treatments, including approvals for patients with limited treatment options. These alternatives cater to patients who face difficulties with daily oral medication regimens. For instance, In December 2022, the U.S. FDA approved Sunlenca (lenacapavir), a novel antiretroviral medication. This approval addresses the needs of adult patients with human immunodeficiency virus type 1 (HIV-1) whose infections are resistant to, intolerant of, or unsafe with other available treatments.
Human immunodeficiency virus therapeutics encompass medical treatments designed to manage and control HIV infections. These therapies primarily involve antiretroviral drugs that inhibit viral replication, thereby preventing or delaying the progression to AIDS. The primary objectives of HIV treatment are to reduce the viral load to undetectable levels, maintain a robust immune system, and prevent virus transmission.
What is the market share of branded drugs in the HIV therapeutics industry?
Branded drugs held a 74.5% market share in 2024, supported by increasing prescriptions for fixed-dose combinations like Biktarvy, Genvoya, and Triumeq.
How big is the global human immunodeficiency virus therapeutics market?
The global HIV therapeutics industry was valued at USD 39 billion in 2024 and is projected to grow at a 3.5% CAGR from 2025 to 2034, driven by the high incidence of HIV infections and advancements in therapeutic treatments.
Who are some of the prominent players in the HIV therapeutics industry?
Key players in the market include AbbVie, Aurobindo Pharma, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Cipla, Dr. Reddy's Laboratories, F. Hoffmann-La Roche, Gilead Sciences, Hetero Drugs, and Johnson & Johnson.
How much revenue did the U.S. generate in the North American HIV therapeutics market in 2024?
The U.S. led the North American HIV therapeutics market with a revenue of approximately USD 14.5 billion in 2024, driven by increased PrEP prescriptions and expanded HIV testing.